Dr. Parkinson to Address 7th Annual Conference on Drug-Drug Interactions
Wednesday May 12, 8:30 am ET
WARWICK, R.I.--(BUSINESS WIRE)--May 12, 2004--MultiCell Technologies, Inc. (OTCBB:EXTI - News) announced today that Dr. Andrew Parkinson, founder and Chief Executive Officer of XenoTech, the Company's licensee, will be a featured speaker at the 7th Annual Conference on Drug-Drug Interactions to be held in San Diego from June 14 - 16, 2004.
XenoTech is dedicated to providing drug metabolism and drug-drug interaction studies to pharmaceutical and chemical companies worldwide. In support of this type of research, XenoTech offers antibodies against Cytochrome P450's, hepatocytes, hepatic and extra-hepatic microsomes, S9, recombinant CYPs, and bDNA probe sets. XenoTech's reputation as a leader in drug metabolism research originated in 1983 with Dr. Andrew Parkinson's studies of cytochrome P450 (CYP) enzymes. Dr. Parkinson founded XenoTech in 1994 to provide products and contract research services to optimize the discovery, development and approval of drugs, food additives, nutraceuticals, agrochemicals, cosmetics and fragrances.
XenoTech's products and services deliver information recommended by the U.S. Food & Drug Administration (FDA) to predict inter-individual variation in safety and drug efficacy, and to explain adverse reactions.
Dr. Parkinson's talk is entitled, "Immortalized and Fresh Human Hepatocytes: Use and Performance in Metabolism, Induction and Toxicity Screening" and will discuss the role of human hepatocytes in preclinical drug development. His presentation will compare fresh and cryopreserved human hepatocytes to MultiCell's human hepatocyte cell line that has the potential to solve the problem of supply and variability that restrict the use of human hepatocytes for enzyme induction and other in vitro screening.
Dr. Parkinson stated, "We believe that MultiCell's immortalized human hepatocytes will become an accepted standard for preclinical testing of new drug compounds. Our studies indicate that no other form of human hepatocyte, including primary human hepatocytes, offers the functionality and consistency of MultiCell's cell lines. We are happy to make this information available to fellow scientists and researchers at conference such as this."
About MultiCell:
MultiCell Technologies, Inc., (EXTI.OB) provides hepatic (liver) cells and cell lines to pharmaceutical companies for drug discovery, and is developing cell-based toxicological and drug screening tests and biologics for use in diagnostic and therapeutic applications. MultiCell's cellular product expertise also enables production of liver-derived therapeutic proteins. The Company's Xenogenics subsidiary is developing the Sybiol® synthetic bio-liver device. MultiCell's corporate and research headquarters are in Warwick, Rhode Island. For more information about MultiCell and its subsidiary, visit www.multicelltechnologies.com.
The matters set forth in this press release are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially. These risks are detailed from time to time in the Company's periodic reports filed with the Securities and Exchange Commission including the Company's Annual Report, Quarterly Reports and other periodic filings. These forward-looking statements speak only as of the date hereof. The Company disclaims any intent or obligation to update these forward-looking statements.
--------------------------------------------------------------------------------
Contact:
MultiCell Technologies Inc.
Jerry Newmin, 401-384-6789
--------------------------------------------------------------------------------
Source: MultiCell Technologies Inc. |
